Stock comparison
Harmony Biosciences Holdings
Madrigal Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
MDGL
Madrigal Pharmaceuticals
Market cap
$11.93B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | MDGL | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 26F | HRMY |
| Benjamin Graham | 60C | 60D | Tie |
| Philip Fisher | 75B | 33F | HRMY |
| Peter Lynch | 62C | 6F | HRMY |
| Joel Greenblatt | 28F | 2F | HRMY |
| Charlie Munger | 62C | 33F | HRMY |
| Terry Smith | 67B | 27F | HRMY |
Side-by-side metrics
| Metric | HRMY | MDGL |
|---|---|---|
| Market cap | $1.75B | $11.93B |
| P/E (TTM) | 11.8x | - |
| EV/EBIT | 6.4x | - |
| ROIC (TTM) | 12.5% | -35.2% |
| Gross margin | 76.55% | 93.07% |
| Net margin | 16.2% | -27.32% |
| Revenue CAGR 5y | 29.85% | - |
| EPS CAGR 5y | 46.45% | -4.88% |
| Debt / Equity | 0.2x | 0.6x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- Net margin16.2%vs -27.32%+159%
- ROIC (TTM)12.5%vs -35.2%+136%
- EPS CAGR 5y46.45%vs -4.88%+110%
- Debt / Equity0.2xvs 0.6x+65%
MDGL leads on
- P/E (TTM)-vs 11.8x+124%
- EV/EBIT-vs 6.4x+116%
- Market cap$11.93Bvs $1.75B+85%
- Gross margin93.07%vs 76.55%+18%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.